Vicore enters into collaboration with Alex Therapeutics to develop new prescription digital therapeutic for patients with IPF
Evidence-based digital interventions that deliver novel and personalized care
Digital Therapeutics (DTx) are evidence-based therapeutic interventions delivered as mobile software applications. They undergo rigorous clinical and regulatory review, ensuring the same high standards of efficacy and safety as with traditional drugs. A DTx can be prescribed by a physician alongside a drug or therapy or as a stand-alone treatment.
Prescription DTx to increase quality of life for IPF patients.
The comprehensive DTx will provide treatment for currently under treated symptoms associated with IPF such as depression and anxiety, improving patient's quality of life.
The all-inclusive digital quit smoking coach.
Currently available for download in over 150 countries globally through the Apple App Store and Google Play.
Autonomous CBT treament targeting obesity.
Are you our partner in developing and commercializing our CBT obesity treatment built on the Alex DTx Platform? Reach out to learn more.
Depression and anxiety treatment for patients diagnosed with breast cancer.
Are you our partner in developing and commercializing our CBT breast cancer treatment built on the Alex DTx Platform? Reach out to learn more.
Empowering patients globally
With a patient-centric mentality, we are driven by our goal of delivering targeted personalized care. Our novel DTx treatments are developed in collaboration with patient groups and deliver targeted, personalized care to patients with overlooked symptoms.
Looking for the Alex – Quit Smoking app? Go to alexquitsmoking.com